anti-EV-D68 mAbs

Anti-EV-D68 mAbs refers to a development program by IDBiologics focused on monoclonal antibodies for the treatment and prevention of Enterovirus D68 (EV-D68) infections. EV-D68 is a non-polio enterovirus that causes severe respiratory illness and has been linked to outbreaks of acute flaccid myelitis (AFM), a serious neurological condition causing muscle weakness and paralysis, primarily in children. The antibodies in this program, which were originally discovered and characterized at Vanderbilt University Medical Center, are designed to bind to the viral capsid and neutralize the virus, preventing it from infecting host cells. As of 2024, the program is in the preclinical stages of development, aiming to address the lack of approved vaccines or specific antiviral therapies for EV-D68.

Other names

Anti-enterovirus D68 monoclonal antibodiesEV-D68 monoclonal antibodiesEV-D-68 monoclonal antibodiesEV-D 68 monoclonal antibodies